We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$10.6B
$48.1M 7.82%
911,182
+57,320
+7% +$3.19M
PTGX icon
2
Protagonist Therapeutics
PTGX
$8.54B
$44.2M 7.18%
981,295
-622,637
-39% -$25.2M
BBIO icon
3
BridgeBio Pharma
BBIO
$16.4B
$36.9M 6%
1,448,470
+183,900
+15% +$4.83M
BOXX icon
4
Alpha Architect 1-3 Month Box ETF
BOXX
$13.1B
$35.2M 5.73%
323,382
-28,100
-8% -$3.04M
ROIV icon
5
Roivant Sciences
ROIV
$23.6B
$34.9M 5.68%
3,025,450
-1,124,559
-27% -$12.8M
IMVT icon
6
Immunovant
IMVT
$7.93B
$32.3M 5.25%
1,131,707
+655,164
+137% +$19.3M
RPRX icon
7
Royalty Pharma
RPRX
$26.2B
$31M 5.05%
1,096,666
-84,666
-7% -$2.35M
KROS icon
8
Keros Therapeutics
KROS
$197M
$25.8M 4.2%
445,068
-103,848
-19% -$5.13M
ASND icon
9
Ascendis Pharma A/S
ASND
$16.5B
$24.1M 3.92%
161,402
+110,139
+215% +$14.9M
ZURA icon
10
Zura Bio
ZURA
$504M
$15.3M 2.49%
+3,770,649
New +$14.1M
ZLAB icon
11
Zai Lab
ZLAB
$2.07B
$12.9M 2.09%
532,454
+510,454
+2,320% +$9.65M
KNSA icon
12
Kiniksa Pharmaceuticals
KNSA
$6.23B
$10.9M 1.77%
436,668
+322,359
+282% +$7.85M
AAM
13
DELISTED
AA Mission Acquisition Corp
AAM
$10.1M 1.65%
+1,010,199
New +$10.1M
MLYS icon
14
Mineralys Therapeutics
MLYS
$2.32B
$8.83M 1.44%
729,401
+704,035
+2,776% +$8.52M
ABUS icon
15
Arbutus Biopharma
ABUS
$845M
$8.04M 1.31%
2,089,321
-1,199,939
-36% -$4.6M
SLDB icon
16
Solid Biosciences
SLDB
$791M
$7.98M 1.3%
1,145,592
-274,830
-19% -$2.23M
MRUS
17
DELISTED
Merus
MRUS
$7.66M 1.25%
153,286
+126,436
+471% +$6.6M
RZLT icon
18
Rezolute
RZLT
$453M
$7.62M 1.24%
1,571,705
-492,257
-24% -$2.26M
PCSC
19
DELISTED
Perceptive Capital Solutions
PCSC
$7.51M 1.22%
750,000
– –
XNCR icon
20
Xencor
XNCR
$1.45B
$6.88M 1.12%
+342,262
New +$6.43M
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.7B
$6.74M 1.1%
+350,206
New +$7.24M
ANAB icon
22
AnaptysBio
ANAB
$1.55B
$6.46M 1.05%
192,720
+36,921
+24% +$1.26M
ABVX
23
Abivax
ABVX
$10.4B
$6.01M 0.98%
521,612
+494,612
+1,832% +$5.93M
RGNX icon
24
Regenxbio
RGNX
$615M
$5.97M 0.97%
569,008
+566,308
+20,974% +$6.9M
BIIB icon
25
Biogen
BIIB
$30.9B
$5.74M 0.93%
+29,625
New +$6.2M
1
2 3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.